Back to Search Start Over

Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures

Authors :
Stodberg, T
McTague, A
Ruiz, AJ
Hirata, H
Zhen, J
Long, P
Farabella, I
Meyer, E
Kawahara, A
Vassallo, G
Stivaros, SM
Bjursell, MK
Stranneheim, H
Tigerschiold, S
Persson, B
Bangash, I
Das, K
Hughes, D
Lesko, N
Lundeberg, J
Scott, RC
Poduri, A
Scheffer, IE
Smith, H
Gissen, P
Schorge, S
Reith, MEA
Topf, M
Kullmann, DM
Harvey, RJ
Wedell, A
Kurian, MA
Stodberg, T
McTague, A
Ruiz, AJ
Hirata, H
Zhen, J
Long, P
Farabella, I
Meyer, E
Kawahara, A
Vassallo, G
Stivaros, SM
Bjursell, MK
Stranneheim, H
Tigerschiold, S
Persson, B
Bangash, I
Das, K
Hughes, D
Lesko, N
Lundeberg, J
Scott, RC
Poduri, A
Scheffer, IE
Smith, H
Gissen, P
Schorge, S
Reith, MEA
Topf, M
Kullmann, DM
Harvey, RJ
Wedell, A
Kurian, MA
Publication Year :
2015

Abstract

The potassium-chloride co-transporter KCC2, encoded by SLC12A5, plays a fundamental role in fast synaptic inhibition by maintaining a hyperpolarizing gradient for chloride ions. KCC2 dysfunction has been implicated in human epilepsy, but to date, no monogenic KCC2-related epilepsy disorders have been described. Here we show recessive loss-of-function SLC12A5 mutations in patients with a severe infantile-onset pharmacoresistant epilepsy syndrome, epilepsy of infancy with migrating focal seizures (EIMFS). Decreased KCC2 surface expression, reduced protein glycosylation and impaired chloride extrusion contribute to loss of KCC2 activity, thereby impairing normal synaptic inhibition and promoting neuronal excitability in this early-onset epileptic encephalopathy.

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1315699037
Document Type :
Electronic Resource